Yankees Score with ...
Health Care: Drugs
Merrimack Pharmaceuticals Inc (MACK: NASDAQ)
$5.20 -0.06 | -1.14%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 5.20 |
| 52 Week High | 11.11 |
| 52 Week Low | 4.06 |
| Avg. Daily Vol. (Mil) | 0.33 |
| Beta (3 year) | 0.00 |
| Share Related Items | |
| Mkt Cap (Mil) | 499.66 |
| Shares Out (Mil) | 96.09 |
| Float (Mil) | 73.35 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.00 |
| Current Ratio | 2.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 9.57 |
| Price/Book | 0.00 |
| Price/Cash Flow | -3.60 |
| Per Share Data | |
| Earnings | -0.99 |
| Sales | 0.54 |
| Book Value | 0.00 |
| Cash Flow | -1.43 |
| Business Summary | |
|---|---|
| Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. | |
| General Information | |
| One Kendall Square
Suite B7201 Cambridge, MA 02139 |
|
| www.merrimackpharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 230 | |
| CEO: Robert J. Mulroy | |
| Short Interest | |
| Current Month (Mil) | 2.47 |
| Previous Month (Mil) | 2.66 |
| Short Interest Ratio (Days) | 6.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -110.00 |
| Return on Investments | -697.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with MACK
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- ProTPG-Axon Capital
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
Latest MACK Headlines from TheStreet
- Merrimack Pharmaceuticals Completes Enrollment Of One Cohort In Neoadjuvant Phase 2 Study Of MM-121 In HER2-Negative Breast Cancer 04.15.13 | 08:04 am
- Merrimack Pharmaceuticals Announces Webcast Of Inaugural Research & Development Day 04.05.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers 03.18.13 | 08:03 am
- Merrimack Reports Fourth Quarter And Full Year 2012 Financial Results 03.14.13 | 08:03 am
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- Merrimack Pharmaceuticals Announces Timing Of Fourth Quarter 2012 Investor Conference Call 02.27.13 | 09:02 am
- Merrimack To Present At The Cowen And Company 33rd Annual Health Care Conference 02.25.13 | 12:02 pm
- Merrimack To Participate In Pancreatic Cancer Panel At The 2013 BIO CEO & Investor Conference 02.07.13 | 12:02 pm
- Merrimack Pharmaceuticals To Present Preclinical Data On Bispecific Antibody MM-111 In ErbB2-Positive Gastric Cancers 01.23.13 | 08:01 am
- Merrimack Pharmaceuticals Initiates Cross-Tumor Study To Investigate Potential Predictive Response Markers For A Developmental Nanotherapeutic Chemotherapy 12.19.12 | 02:12 pm
Press Releases for MACK
- Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model - PR Newswire 04.10.13 | 09:04 am
- Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor - PR Newswire 04.04.13 | 08:04 am
- Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies - PR Newswire 04.02.13 | 09:04 am
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data For Novel Agent To Treat HER2-positive Breast Cancer And Preclinical Data On Companion Diagnostic - PR Newswire 12.10.12 | 09:12 am
- Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer - PR Newswire 11.27.12 | 09:11 am
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers - PR Newswire 10.02.12 | 08:10 am
- Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers - PR Newswire 09.18.12 | 11:09 am
- Merrimack Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering - PR Newswire 03.28.12 | 11:03 pm
Partner Headlines for MACK
- After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC - NASDAQ 11.16.12 | 09:11 pm
- Morning Market Losers - Benzinga 09.25.12 | 09:09 am
- 5 Low-Debt Biotech Stocks Forecasted For Growth - Seeking Alpha 09.22.12 | 09:09 am
- Jim Cramer Watchdog: SELL Morgan Stanley and 'BUY, BUY, BUY' These 3 HOT Stocks - Wall St. Cheat Sheet 07.20.12 | 11:07 am
